Dupixent sales growth
Percentage growth in sales of Dupixent (dupilumab).
Unit Percent Industry Pharmaceuticals
Records
1
Regions
1
Period
2026
Sources
1
The chart
The figure
One published observation so far. A chart follows as soon as a second period is published.
Dupixent sales growth
Global, Q2 2026
37.6%
Source: Sanofi · CC BY 4.0 · statorigin.org
Every record
All records
1 record · 1 region · 2026
Primary documents
Sources
1 document. Each links to the publisher's own copy.
| Document | Publisher | Published | Data points |
|---|---|---|---|
| Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded | Sanofi | 30 Jul 2026 | 1 |
Cite & reuse
Cite this page
Data on this page is published under CC BY 4.0. You may reuse it, including commercially, provided you attribute it. To cite one figure, open its record: each carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Dupixent sales growth. Retrieved from https://statorigin.org/indicators/dupixent-sales-growth